❤️ HEART FIRST PROFILE
Men with cardiovascular disease have significantly lower testosterone than age-matched healthy controls. The relationship runs in both directions: low T worsens lipid profiles, raises inflammatory markers, and increases visceral fat. The TRAVERSE trial (2023) confirmed testosterone normalization is cardiovascular-safe in hypogonadal men.
Heart First targets the cardiometabolic overlap — mitochondrial function, endothelial health, inflammation, and the hormonal axis — with compounds that have direct cardiovascular evidence, not just antioxidant theory.
Build my protocol — freeTHE MECHANISM
“Low testosterone is an independent predictor of all-cause and cardiovascular mortality in men with established coronary artery disease — with a hazard ratio of 2.1 for major adverse events in the lowest testosterone quartile.”
Malkin CJ et al., Heart (2010) — prospective cohort, n=930 men with coronary artery disease
The mechanism is multi-pathway: testosterone directly modulates endothelial nitric oxide synthase, reduces inflammatory cytokines, and improves insulin sensitivity. Men with low testosterone are more likely to have elevated CRP, fibrinogen, and visceral fat — all independent cardiac risk markers.
HEART FIRST STACK
Ubiquinol (the active, reduced form) is the primary electron carrier in mitochondrial ATP production — cardiomyocytes are the most CoQ10-dense cells in the body. Statin use depletes CoQ10 directly. AM dosing with a fat-containing meal maximizes absorption of this lipid-soluble compound.
Reduces serum triglycerides by 15–30% in meta-analyses of RCTs. EPA reduces systemic inflammatory cytokines (IL-6, TNF-alpha) that drive endothelial dysfunction. DHA reduces platelet aggregation. The AHA endorses omega-3 at 1–4g for established cardiovascular disease.
Vitamin D deficiency is independently associated with higher rates of heart failure, hypertension, and arterial stiffness. D3 receptors are expressed in vascular smooth muscle and cardiomyocytes. Men with testosterone in the low-normal range are more likely to be D3-deficient.
Aged garlic extract (Kyolic) reduces systolic blood pressure by 7–9 mmHg in meta-analyses of hypertensive adults. The mechanism: S-allylcysteine reduces vascular oxidative stress and increases nitric oxide bioavailability, improving arterial compliance. AM dosing reduces GI sensitivity.
Magnesium deficiency is associated with higher rates of arrhythmia, hypertension, and endothelial dysfunction. PM glycinate improves sleep architecture, which drives HRV recovery — the cardiovascular metric most responsive to magnesium supplementation. Also reduces SHBG for free testosterone.
Precursor to glutathione — the primary intracellular antioxidant. NAC reduces oxidized LDL and homocysteine, both cardiovascular risk markers. PM timing reduces any mild GI discomfort. Particularly valuable if homocysteine is elevated on labs.
Berberine activates AMPK — the same pathway as metformin. In RCTs it reduces LDL cholesterol, triglycerides, and fasting glucose with effect sizes comparable to low-dose statins. If metabolic markers (glucose, insulin, TG) are elevated alongside cardiovascular risk, this is the highest-leverage addition.
MEDICAL NOTE
If you're on statins, check with your cardiologist about CoQ10 depletion. If on blood thinners, high-dose omega-3 and garlic have mild antiplatelet effects — disclose to your prescriber. Berberine may interact with metformin; monitor blood glucose. This stack is designed for lifestyle optimization alongside, not instead of, medical care.
“My cardiologist was surprised my HRV had improved 12 points in four months. I hadn't changed my meds. Heart First was the only variable I'd added. He wanted to know what was in it.”
Thomas B., 52
HEART FIRST PROFILE
COMMON QUESTIONS
FOUNDING MEMBERS
$39/mo Essential or $69/mo Full Protocol — price locked forever.